NOXXON Enrolls First Patient in the Second Dose Cohort of Trial Combining NOX-A12 With Radiotherapy in Newly Diagnosed Brain ...
30 Juin 2020 - 6:00PM
Business Wire
Regulatory News:
NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX)
(Paris:ALNOX), a biotechnology company focused on improving
cancer treatments by targeting the tumor microenvironment (TME),
announced today the enrollment and first treatment of a patient
with newly diagnosed brain cancer in the middle dose cohort of the
phase 1/2 clinical trial. The study investigates three dose
regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with
external-beam radiotherapy in newly diagnosed brain cancer
patients.
Once the newly enrolled patient in the second cohort has
received a four-week treatment of NOX-A12 and radiotherapy, the
Data Safety Monitoring Board will convene to determine whether it
is safe to recruit the remaining two patients into the cohort.
“Recruitment into this trial currently continues in our study
centers, despite the challenges that hospital staff face as a
result of the COVID-19 pandemic,” commented Aram Mangasarian, CEO
of NOXXON. “Six months of data from the first cohort of patients
should be available in October 2020, and from the second and third
cohorts at the end of Q1 2021 and mid-2021, respectively. As a
measure to ensure the timely completion of the study under the
challenging conditions of the COVID-19 pandemic, we are currently
preparing the inclusion of three additional clinical sites to
increase recruitment capacity.”
About NOXXON
NOXXON’s oncology-focused pipeline acts on the tumor
microenvironment (TME) and the cancer immunity cycle by breaking
the tumor protection barrier and blocking tumor repair. By
neutralizing chemokines in the tumor microenvironment, NOXXON’s
approach works in combination with other forms of treatment to
weaken tumor defenses against the immune system and enable greater
therapeutic impact. Building on extensive clinical experience and
safety data, the lead program NOX-A12 has delivered top-line data
from a Keytruda® combination trial in metastatic colorectal and
pancreatic cancer patients and further studies are being planned in
these indications. In September 2019 the company initiated an
additional trial with NOX-A12 in brain cancer in combination with
radiotherapy. The combination of NOX-A12 and radiotherapy has been
granted orphan drug status in the US and EU for the treatment of
certain brain cancers. The company’s second clinical-stage asset
NOX-E36 is a Phase 2 TME asset targeting the innate immune system.
NOXXON plans to test NOX‑E36 in patients with solid tumors both as
a monotherapy and in combination. Further information can be found
at: www.noxxon.com
Keytruda® is a registered trademark of Merck Sharp & Dohme
Corp
https://www.linkedin.com/company/noxxon-pharma-ag
https://twitter.com/noxxon_pharma
Disclaimer
Certain statements in this communication contain formulations or
terms referring to the future or future developments, as well as
negations of such formulations or terms, or similar terminology.
These are described as forward-looking statements. In addition, all
information in this communication regarding planned or future
results of business segments, financial indicators, developments of
the financial situation or other financial or statistical data
contains such forward-looking statements. The company cautions
prospective investors not to rely on such forward-looking
statements as certain prognoses of actual future events and
developments. The company is neither responsible nor liable for
updating such information, which only represents the state of
affairs on the day of publication.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200630005738/en/
NOXXON Pharma N.V. Aram Mangasarian, Ph.D., Chief
Executive Officer Tel. +49 (0) 30 726247 0
amangasarian@noxxon.com
Trophic Communications Gretchen Schweitzer or Joanne
Tudorica Tel. +49 (0) 89 2388 7730 or +49 (0) 176 2103 7191
schweitzer@trophic.eu
NewCap Arthur Rouillé Tel. +33 (0) 1 44 71 00 15
arouille@newcap.fr